Corrigendum to "Suppression of TLR4 prevents diabetic bone loss by regulating FTO-mediated mA modification" [Int. Immunopharmacol. 122 (2023) 110510].

Int Immunopharmacol

Department of Endocrinology, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Department of Endocrinology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China; Clinical Research Center for Me

Published: January 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2024.113723DOI Listing

Publication Analysis

Top Keywords

corrigendum "suppression
4
"suppression tlr4
4
tlr4 prevents
4
prevents diabetic
4
diabetic bone
4
bone loss
4
loss regulating
4
regulating fto-mediated
4
fto-mediated modification"
4
modification" [int
4

Similar Publications

Corrigendum to "Ginkgolide B effectively mitigates neuropathic pain by suppressing the activation of the NLRP3 inflammasome through the induction of mitophagy in rats" [Biomed. Pharmacother. 177 (2024) 117006].

Biomed Pharmacother

August 2025

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, Zhejiang, China; The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejian

View Article and Find Full Text PDF